surmount-1 tirzepatide trial obesity without diabetes Tirzepatide's Surmount-4 Trial Reveals Groundbreaking Results

SURMOUNT-4 results just published in @JAMA_current 🛑Stopping #tirzepatide leads to regain of the majority of the lost weight. Is this a surprising result ⁉️ No #Obesity is a chronic disease and requires

28.76

★★★★☆4.8 (126)

Tirzepatide cuts diabetes risk by 94% in SURMOUNT-1 trial

28.36

★★★★★4.9 (98)

For the first time, tirzepatide and semaglutide were put in the same trial. SURMOUNT-5. Phase 3b RCT. 751 adults with obesity, no diabetes. 72 weeks. Both drugs at maximum tolerated dose. The

22.75

★★★★★5.0 (157)

Weight reduction with different doses of Tirzepatide in Surmount 1

24.12

★★★★★4.7 (84)

Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial

20.24

★★★★★4.9 (203)

Efficacy and safety of once-weekly tirzepatide in Japanese patients with obesity disease (SURMOUNT-J): a multicentre, randomised, double-blind, placebo-controlled phase 3 trial

29.35

★★★★★5.0 (176)

Early‐Onset Obesity and Tirzepatide Treatment: A Post Hoc Analysis of the SURMOUNT Clinical Trials - Gourgari - 2025 - Obesity

25.03

★★★★★4.8 (132)